Members Trust Co Purchases 874 Shares of Pfizer Inc. (NYSE:PFE)

Members Trust Co grew its holdings in Pfizer Inc. (NYSE:PFE) by 3.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,778 shares of the biopharmaceutical company’s stock after acquiring an additional 874 shares during the period. Members Trust Co’s holdings in Pfizer were worth $688,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. LGT Group Foundation boosted its stake in Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares during the last quarter. ORG Partners LLC lifted its position in Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares during the last quarter. Kempner Capital Management Inc. bought a new stake in shares of Pfizer in the 1st quarter worth about $2,439,000. Commerzbank Aktiengesellschaft FI grew its position in Pfizer by 29.1% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 342,361 shares of the biopharmaceutical company’s stock worth $9,579,000 after acquiring an additional 77,073 shares in the last quarter. Finally, First Foundation Advisors increased its stake in Pfizer by 15.3% during the first quarter. First Foundation Advisors now owns 155,951 shares of the biopharmaceutical company’s stock worth $4,328,000 after acquiring an additional 20,670 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Up 0.9 %

PFE stock traded up $0.25 on Tuesday, hitting $29.33. 16,980,619 shares of the company’s stock were exchanged, compared to its average volume of 37,221,969. The firm has a 50 day moving average price of $29.02 and a two-hundred day moving average price of $28.40. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $33.92. The stock has a market cap of $166.20 billion, a P/E ratio of -494.00, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.73%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.